NCT05608369 2025-04-04
HPV
Case Comprehensive Cancer Center
Phase 2 Withdrawn
Clinical Trials
11 trialsNCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03022565 2020-02-06
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
University of Miami
Phase EARLY_PHASE1 Withdrawn
NCT00837174 2017-09-19
COMBOSTAT
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT01501370 2016-05-10
ZLd_Ld
University of Turin, Italy
Phase 2 Withdrawn
NCT01386398 2015-01-21
Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Withdrawn
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01695057 2014-01-28
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
University of Southern California
Phase NA Withdrawn
NCT01608139 2012-10-19
Study of Curcumin, Vorinostat, and Sorafenib
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01492881 2012-05-11
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01353482 2012-03-22
MESO-02
University College, London
Phase 1/2 Withdrawn